by Immunotherapy has revolutionized the treatment landscape for kidney cancer, leading to improved survival rates for metastatic patients. However, not all individuals respond positively to this innovative therapy. A research team from the University of Leuven, in collaboration with the Computational Biomedicine Group at the University of Innsbruck, has made a significant stride in predicting which patients will benefit from immunotherapy.
The team’s findings, published in the prestigious journal Nature Medicine, offer new possibilities for even more effective treatments. Every year, approximately 1,300 individuals in Austria are diagnosed with kidney cancer. While immunotherapy has significantly increased the five-year survival rate for these patients, not every individual responds positively.
To better understand the reasons behind the varying efficacy of Immunotherapy and to improve the prediction of successful treatment outcomes, the Leuven research team conducted an extensive retrospective study. They analyzed a large dataset of kidney cancer patients who had undergone immunotherapy treatment at UZ Leuven over the past decade. By meticulously examining the patients’ clinical and molecular data, the team identified a novel biomarker that can predict immunotherapy success. This discovery is expected to lead to more personalized and effective treatments for kidney cancer patients.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
